Skip to main content
main-content

Video commentaries


Expert commentaries from clinicians and researchers on clinical trials, guidelines and topical issues in diabetes care.


09-20-2019 | Heart failure | Video | Article

Researcher comment: The DEFINE-HF trial results

Mikhail Kosiborod outlines the findings from the DEFINE-HF trial, and discusses the possible reasons why dapagliflozin had an impact on one primary endpoint but not the other (5:48).

09-20-2019 | Nephropathy | Video | Article

Expert commentary: The PRIORITY trial results

Luigi Gnudi discusses the findings of the PRIORITY trial and addresses whether diabetologists should consider intervening earlier in diabetic nephropathy (4:08).

09-20-2019 | Insulin degludec | Video | Article

Researcher comment: The CONCLUDE trial

Athena Philis-Tsimikas discusses which patients may benefit the most from treatment with long-acting insulins, and how the data from CONCLUDE compare with real-world study findings (2:38).

09-19-2019 | Medications | Video | Article

Expert commentary: Trial results of imeglimin in type 2 diabetes

John Wilding comments on study results highlighting that imeglimin, an agent targeting mitochondrial bioenergetics, may represent a novel therapeutic approach for type 2 diabetes (2:17).

09-19-2019 | Vildagliptin | Highlight | Article

Expert commentary: The VERIFY trial results

Amrit Lamba discusses how the findings of VERIFY may influence how primary care practitioners will approach first-line treatment of people with type 2 diabetes (4:32).

09-19-2019 | Heart failure | Video | Article

Expert commentary: DAPA-HF and DEFINE-HF trial results

Lars Rydén discusses how the results of the DAPA-HF and DEFINE-HF trials will impact treatment decisions for patients with heart failure (6:38).

09-19-2019 | Heart failure | Video | Article

Researcher comment: The DAPA-HF trial results

John McMurray talks about the results of the DAPA-HF trial, discussing whether the benefits of dapagliflozin for patients with heart failure could be extended to other SGLT2 inhibitors, and the next steps for research (3:29).

06-20-2019 | Diabetes prevention | ADA 2019 | Article

The D2d trial: An Indian perspective

Deep Dutta, from New Delhi, talks about the implications of the D2d trial findings for doctors practicing in India (2:51).

06-13-2019 | Prediabetes | ADA 2019 | Article

Expert commentary: The RISE study

With all three RISE studies now published, John Wilding reflects on the pathophysiological differences between children and adults with type 2 diabetes (2:12).

06-13-2019 | Physical activity | ADA 2019 | Article

Expert highlights: High performance exercise and type 1 diabetes

John Wilding talks about research presented at the ADA Scientific Sessions looking at the management of type 1 diabetes in elite athletes (3:18).

06-13-2019 | Insulin degludec/Liraglutide | ADA 2019 | Article

Expert commentary: The DUAL VIII trial

Sanjay Kalra discusses the implications of the DUAL VIII trial, which looked at the effect of IDegLira versus glargine on the time to treatment intensification in people with type 2 diabetes (2:39).

06-12-2019 | Linagliptin | ADA 2019 | Article

Expert commentary: An endocrinologist's view of the CAROLINA trial

Sanjay Kalra tells us why he is so reassured by the findings of the CAROLINA trial pitting linagliptin against glimepiride (2:38).

06-12-2019 | Linagliptin | ADA 2019 | Article

Clinical takeaway: The CAROLINA trial

John Wilding outlines the key take-home message from the CAROLINA trial comparing the cardiovascular risk profile of the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride (0:37).

06-11-2019 | Semaglutide | ADA 2019 | Article

Researcher comment: The PIONEER 6 oral semaglutide cardiovascular outcomes study

PIONEER 6 lead investigator Mansoor Husain discusses the results of the trial, and how oral and injectable semaglutide compare and can be used in the clinic (4:40).

06-10-2019 | ADA 2019 | Article

Expert highlights: ADA session “Making a difference in 5 minutes”

Lori Berard gives an overview of the ADA session “Making a difference in five minutes: Interventions in diabetes for anyone.” (2:00)

Image Credits